Cardiology

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

Parag Joshi, MD, highlights CAC scoring’s value as a prognostic tool for lipid-lowering therapy.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the suboptimal number of patients at risk of long-term complications due to nonadherence.

Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the importance of exercise, medical interventions, and smoking cessation for PAD care.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Preview the biggest anticipated FDA decisions of Q3 2026, including atacicept for IgAN, mRNA flu vaccine, Furoscix ReadyFlow, and more.

A study from UC Berkeley has unveiled an AI model that outperforms standard clinical tests in identifying patients at risk of sudden cardiac death.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

John Giacona, PhD, PA-C, says identifying pulmonary hypertension early, distinguishing its type, and engaging critically with clinical evidence are paramount.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.